Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, et al.
PLoS Computational Biology (2019) Vol. 15, Iss. 3, pp. e1006658-e1006658
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Molecular profiling for precision cancer therapies
Eoghan Ruadh Malone, Marc Oliva, Peter Sabatini, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 703
Artificial intelligence in COVID-19 drug repurposing
Yadi Zhou, Fei Wang, Jian Tang, et al.
The Lancet Digital Health (2020) Vol. 2, Iss. 12, pp. e667-e676
Open Access | Times Cited: 544
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 251
AlphaFold, Artificial Intelligence (AI), and Allostery
Ruth Nussinov, Mingzhen Zhang, Yonglan Liu, et al.
The Journal of Physical Chemistry B (2022) Vol. 126, Iss. 34, pp. 6372-6383
Open Access | Times Cited: 107
Multi-OMICS approaches in cancer biology: New era in cancer therapy
Sohini Chakraborty, Gaurav Sharma, Sricheta Karmakar, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 5, pp. 167120-167120
Closed Access | Times Cited: 44
Perspectives on Computational Enzyme Modeling: From Mechanisms to Design and Drug Development
Kwangho Nam, Yihan Shao, Dan Thomas Major, et al.
ACS Omega (2024)
Open Access | Times Cited: 22
Limitations and challenges in protein stability prediction upon genome variations: towards future applications in precision medicine
Tiziana Sanavia, Giovanni Birolo, Ludovica Montanucci, et al.
Computational and Structural Biotechnology Journal (2020) Vol. 18, pp. 1968-1979
Open Access | Times Cited: 121
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
Yibin Xu, Ding Xue, Armand Bankhead, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14276-14307
Open Access | Times Cited: 110
Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine
Stanisław Supplitt, Paweł Karpiński, Maria Sa̧siadek, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1422-1422
Open Access | Times Cited: 103
Integrated Computational Approaches and Tools for Allosteric Drug Discovery
Olivier Sheik Amamuddy, Wayde Veldman, Colleen Varaidzo Manyumwa, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 847-847
Open Access | Times Cited: 92
Allosteric drugs and mutations: chances, challenges, and necessity
Enrico Guarnera, Igor N. Berezovsky
Current Opinion in Structural Biology (2020) Vol. 62, pp. 149-157
Closed Access | Times Cited: 90
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, et al.
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167569-167569
Open Access | Times Cited: 47
Anticancer drugs: How to select small molecule combinations?
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 503-519
Closed Access | Times Cited: 14
AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations
Zhen Wah Tan, Enrico Guarnera, Wei-Ven Tee, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. W1, pp. W116-W124
Open Access | Times Cited: 70
Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
Min Hwa Shin, Jiyoung Kim, Siyoung A. Lim, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2531-2531
Open Access | Times Cited: 67
A systems approach to clinical oncology uses deep phenotyping to deliver personalized care
James T. Yurkovich, Qiang Tian, Nathan D. Price, et al.
Nature Reviews Clinical Oncology (2019) Vol. 17, Iss. 3, pp. 183-194
Closed Access | Times Cited: 55
Unsupervised Learning and Multipartite Network Models: A Promising Approach for Understanding Traditional Medicine
Mohieddin Jafari, Yinyin Wang, Ali Amiryousefi, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 51
A new precision medicine initiative at the dawn of exascale computing
Ruth Nussinov, Hyunbum Jang, Guy Nir, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 46
Exploring the Allosteric Territory of Protein Function
Wei-Ven Tee, Zhen Wah Tan, Keene Lee, et al.
The Journal of Physical Chemistry B (2021) Vol. 125, Iss. 15, pp. 3763-3780
Closed Access | Times Cited: 42
Breakthroughs in AI and Multi-Omics for Cancer Drug Discovery: A Review
Israr Fatima, Abdur Rehman, Yanheng Ding, et al.
European Journal of Medicinal Chemistry (2024) Vol. 280, pp. 116925-116925
Closed Access | Times Cited: 6
On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism
Wei-Ven Tee, Enrico Guarnera, Igor N. Berezovsky
Journal of Molecular Biology (2019) Vol. 431, Iss. 19, pp. 3933-3942
Closed Access | Times Cited: 43
Mutations of Intrinsically Disordered Protein Regions Can Drive Cancer but Lack Therapeutic Strategies
Bálint Mészáros, Borbála Hajdu-Soltész, András Zeke, et al.
Biomolecules (2021) Vol. 11, Iss. 3, pp. 381-381
Open Access | Times Cited: 40
A New View of Activating Mutations in Cancer
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Cancer Research (2022) Vol. 82, Iss. 22, pp. 4114-4123
Open Access | Times Cited: 26
Bipartite network models to design combination therapies in acute myeloid leukaemia
Mohieddin Jafari, Mehdi Mirzaie, Jie Bao, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 25
Learning About Allosteric Drugs and Ways to Design Them
Zhen Wah Tan, Wei-Ven Tee, Igor N. Berezovsky
Journal of Molecular Biology (2022) Vol. 434, Iss. 17, pp. 167692-167692
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top